Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5955895 | 1.00 | POLB (0.40) | POLBKMT2AMEN1L3MBTL1NPSR1 | |
| SCHEMBL5954873 | 1.00 | POLB (0.40) | POLBKMT2AMEN1L3MBTL1NPSR1 | |
| Benzene SCHEMBL5954954 | 0.82 | MEN1 (0.47) | POLBKMT2AMEN1L3MBTL1ALDH1A1 | |
| Cyclopropane SCHEMBL5955262 | 0.82 | MEN1 (0.41) | POLBKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL5954948 | 0.81 | L3MBTL1 (0.40) | POLBKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL5415817 | 0.81 | L3MBTL1 (0.40) | POLBKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL5955256 | 0.81 | L3MBTL1 (0.40) | POLBKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL4044696 | 0.81 | MEN1 (0.44) | POLBKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL4037754 | 0.81 | MEN1 (0.44) | POLBKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL5421601 | 0.78 | FKBP1A (0.51) | POLBKMT2AMEN1NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20060089357-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | US | disclosed |
| US-7030116-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1515726-A1 | MORPHOLINE AND TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004002491-A1 | MORPHOLINE AND TETRAHYDROPYRAN DRIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002491-A1 | MORPHOLINE AND TETRAHYDROPYRAN DRIVATIVES AND THEIR USE AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACUETICALS INC. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105099-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | POLB 1961/4885KMT2A 4602/4885MEN1 4458/4885 |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | POLB 2141/4885KMT2A 4623/4885MEN1 4485/4885 |
| US-20060089357-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | POLB 1961/4885KMT2A 4602/4885MEN1 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.